Inhibrx Biosciences, Inc. INBX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$33.44M+22.8% | -$32.83M— | -$35.26M+19.6% | -$28.65M-102% | -$43.31M+45.0% | ||
| $537K-20.4% | $564K-18.1% | $582K-23.4% | $662K+39.4% | $675K+87.5% | ||
| $2.65M+8.3% | $2.74M-8.0% | $3.18M+7.1% | $2.77M-94.0% | $2.45M-61.7% | ||
| $732K+37.3% | $642K— | $638K— | $626K-23.9% | $533K-57.1% | ||
| $0+100% | —— | -$127K— | —— | -$200K— | ||
| $2.82M+898% | -$829K— | -$1.52M— | -$600K-103% | -$353K-109% | ||
| -$10.19M-453% | -$1.43M— | -$1.52M-125% | -$4.3M-120% | $2.88M-64.1% | ||
| $0+100% | $0-100% | $22K— | $6K-99.7% | -$28K-102% | ||
| -$549K-221% | -$535K-664% | -$522K-55.4% | -$367K+27.6% | -$171K+65.5% | ||
| $9K-47.1% | -$706K-394% | -$3K+99.6% | $672K+354% | $17K-97.2% | ||
| -$38.03M-5.9% | -$30.12M+31.1% | -$33.82M-11.7% | -$29.95M+47.8% | -$35.9M+43.1% | ||
| $0-100% | —— | $10K-96.0% | —— | $21K-98.1% | ||
| $0+100% | —— | -$7K+97.2% | —— | -$21K+98.1% | ||
| $471K— | $1.25M— | $352K— | $0-100% | $0-100% | ||
| $75.46M-24.4% | $1.25M— | $352K— | $0-100% | $99.84M+158% | ||
| $37.44M-41.4% | -$28.87M+34.0% | —— | —— | $63.92M+351% | ||
| $2.78M+114% | $2.51M— | $2.54M— | $2.54M-44.9% | $1.3M-81.2% | ||
| $0— | —— | —— | $2K0.0% | $0— | ||
| $732K+37.3% | $642K— | $638K— | $626K-23.9% | $533K-57.1% | ||
| $0+100% | —— | —— | —— | -$23K— | ||
| -$549K-221% | -$535K-664% | -$522K-55.4% | -$367K+27.6% | -$171K+65.5% | ||
| $9K-47.1% | -$706K-394% | -$3K+99.6% | $672K+354% | $17K-97.2% | ||
| $1.06M+246% | -$423K+83.8% | -$25K+99.3% | -$222K-120% | -$730K-131% | ||
| —— | $450.75K-5.0% | $450.75K-5.0% | $450.75K-5.0% | $450.75K-5.0% | ||
| $483K+11.3% | —— | $456K-6.2% | $444K-6.7% | $434K-6.7% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $0-100% | —— | —— | —— | $125K— | ||
| —— | $31.25K— | $31.25K— | $31.25K— | $31.25K— | ||
| -$549K-221% | -$535K-664% | -$522K-55.4% | -$367K+27.6% | -$171K+65.5% | ||
| —— | $430K— | $430K— | $430K— | $430K— | ||
| $1.29M-25.1% | —— | —— | —— | $1.72M— | ||
| $74.99M-25.0% | —— | —— | —— | $99.97M— | ||
| —— | $0-100% | $0— | $0— | $0— | ||
| $0— | —— | —— | $2K0.0% | $0— | ||
| -$38.03M-5.9% | -$30.12M+31.1% | -$33.83M-10.8% | -$29.95M+48.9% | -$35.92M+44.0% | ||
| -$38.03M-5.9% | -$30.12M+31.1% | -$33.83M-10.8% | -$29.95M+48.9% | -$35.92M+44.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Inhibrx Biosciences, Inc. generate?
- Inhibrx Biosciences, Inc. (INBX) generated -$131.9M in operating cash flow over the trailing twelve months.
- What is Inhibrx Biosciences, Inc.'s free cash flow?
- After $47.0K of capital expenditures, Inhibrx Biosciences, Inc.'s free cash flow was -$131.9M over the trailing twelve months, up 21.8% year over year.
- Where does Inhibrx Biosciences, Inc.'s cash flow data come from?
- Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
